Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the effect of treatment with epoetin alfa
(recombinant human erythropoietin) or placebo on anemia related quality-of-life and anemia in
hormone-refractory (not responding to hormone therapy) prostate cancer patients.